CN108017707A - A kind of biologically active polypeptide QPVLGPVRGP and its preparation method and application - Google Patents
A kind of biologically active polypeptide QPVLGPVRGP and its preparation method and application Download PDFInfo
- Publication number
- CN108017707A CN108017707A CN201711319270.9A CN201711319270A CN108017707A CN 108017707 A CN108017707 A CN 108017707A CN 201711319270 A CN201711319270 A CN 201711319270A CN 108017707 A CN108017707 A CN 108017707A
- Authority
- CN
- China
- Prior art keywords
- qpvlgpvrgp
- biologically active
- active polypeptide
- polypeptide
- mouse
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 137
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 116
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 110
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 230000036541 health Effects 0.000 claims abstract description 17
- 235000013305 food Nutrition 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 13
- 230000002519 immonomodulatory effect Effects 0.000 claims abstract description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 8
- 230000003005 anti-senility effect Effects 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 20
- 239000000047 product Substances 0.000 claims description 19
- 230000001900 immune effect Effects 0.000 claims description 13
- 235000013336 milk Nutrition 0.000 claims description 13
- 239000008267 milk Substances 0.000 claims description 13
- 210000004080 milk Anatomy 0.000 claims description 13
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 230000033228 biological regulation Effects 0.000 claims description 12
- 230000003712 anti-aging effect Effects 0.000 claims description 10
- 230000008859 change Effects 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 8
- 230000032050 esterification Effects 0.000 claims description 6
- 238000005886 esterification reaction Methods 0.000 claims description 6
- 230000013595 glycosylation Effects 0.000 claims description 6
- 238000006206 glycosylation reaction Methods 0.000 claims description 6
- 230000000640 hydroxylating effect Effects 0.000 claims description 6
- 230000021736 acetylation Effects 0.000 claims description 5
- 238000006640 acetylation reaction Methods 0.000 claims description 5
- 239000002537 cosmetic Substances 0.000 claims description 5
- 230000026731 phosphorylation Effects 0.000 claims description 5
- 238000006366 phosphorylation reaction Methods 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 235000013365 dairy product Nutrition 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- 241000005787 Cistanche Species 0.000 claims description 2
- 230000007365 immunoregulation Effects 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 238000010353 genetic engineering Methods 0.000 claims 1
- 239000002777 nucleoside Substances 0.000 claims 1
- 125000003835 nucleoside group Chemical group 0.000 claims 1
- 238000002474 experimental method Methods 0.000 abstract description 27
- 230000032683 aging Effects 0.000 abstract description 17
- 210000004698 lymphocyte Anatomy 0.000 abstract description 13
- 238000004458 analytical method Methods 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 8
- 210000002540 macrophage Anatomy 0.000 abstract description 8
- 238000000338 in vitro Methods 0.000 abstract description 7
- 108090000790 Enzymes Proteins 0.000 abstract description 6
- 102000004190 Enzymes Human genes 0.000 abstract description 6
- COYSIHFOCOMGCF-UHFFFAOYSA-N Val-Arg-Gly Natural products CC(C)C(N)C(=O)NC(C(=O)NCC(O)=O)CCCN=C(N)N COYSIHFOCOMGCF-UHFFFAOYSA-N 0.000 abstract description 3
- YPFFHGRJCUBXPX-NHCYSSNCSA-N Gln-Pro-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCC(N)=O)C(O)=O YPFFHGRJCUBXPX-NHCYSSNCSA-N 0.000 abstract description 2
- YFBBUHJJUXXZOF-UWVGGRQHSA-N Leu-Gly-Pro Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O YFBBUHJJUXXZOF-UWVGGRQHSA-N 0.000 abstract description 2
- COYSIHFOCOMGCF-WPRPVWTQSA-N Val-Arg-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CCCN=C(N)N COYSIHFOCOMGCF-WPRPVWTQSA-N 0.000 abstract description 2
- 230000003035 anti-peroxidant effect Effects 0.000 abstract description 2
- 108010091092 arginyl-glycyl-proline Proteins 0.000 abstract description 2
- 208000015181 infectious disease Diseases 0.000 abstract description 2
- 230000001717 pathogenic effect Effects 0.000 abstract description 2
- 108010053725 prolylvaline Proteins 0.000 abstract description 2
- 230000036259 sexual stimuli Effects 0.000 abstract description 2
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 86
- 238000003304 gavage Methods 0.000 description 31
- 239000000243 solution Substances 0.000 description 31
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 28
- 238000010171 animal model Methods 0.000 description 25
- 241001465754 Metazoa Species 0.000 description 22
- 210000000952 spleen Anatomy 0.000 description 21
- 239000011347 resin Substances 0.000 description 20
- 229920005989 resin Polymers 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 15
- 238000005516 engineering process Methods 0.000 description 15
- 239000003153 chemical reaction reagent Substances 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 108010076119 Caseins Proteins 0.000 description 11
- 102000011632 Caseins Human genes 0.000 description 11
- 229930040373 Paraformaldehyde Natural products 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 239000013642 negative control Substances 0.000 description 11
- 229920002866 paraformaldehyde Polymers 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 239000012980 RPMI-1640 medium Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 9
- 210000000056 organ Anatomy 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 8
- -1 aromatic amino acid Chemical class 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 238000007689 inspection Methods 0.000 description 8
- 235000021247 β-casein Nutrition 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
- 102100040247 Tumor necrosis factor Human genes 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 239000008363 phosphate buffer Substances 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 229940126678 chinese medicines Drugs 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 239000003182 parenteral nutrition solution Substances 0.000 description 6
- 150000003053 piperidines Chemical class 0.000 description 6
- 206010003694 Atrophy Diseases 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 230000037444 atrophy Effects 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 230000008014 freezing Effects 0.000 description 5
- 238000007710 freezing Methods 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 210000003024 peritoneal macrophage Anatomy 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108010077544 Chromatin Proteins 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 210000003483 chromatin Anatomy 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000008520 organization Effects 0.000 description 4
- 230000004792 oxidative damage Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 210000001835 viscera Anatomy 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 3
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 210000005252 bulbus oculi Anatomy 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 235000020247 cow milk Nutrition 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000004042 decolorization Methods 0.000 description 3
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000003517 fume Substances 0.000 description 3
- 230000031700 light absorption Effects 0.000 description 3
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- UWSONZCNXUSTKW-UHFFFAOYSA-N 4,5-Dimethylthiazole Chemical compound CC=1N=CSC=1C UWSONZCNXUSTKW-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- NELVFWFDOKRTOR-SDDRHHMPSA-N His-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC2=CN=CN2)N)C(=O)O NELVFWFDOKRTOR-SDDRHHMPSA-N 0.000 description 2
- DPURXCQCHSQPAN-AVGNSLFASA-N Leu-Pro-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DPURXCQCHSQPAN-AVGNSLFASA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- CUTSCJHLMGPBEJ-UHFFFAOYSA-N [N].CN(C)C=O Chemical compound [N].CN(C)C=O CUTSCJHLMGPBEJ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 108010057821 leucylproline Proteins 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 229920006324 polyoxymethylene Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010183 spectrum analysis Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- QMLXCJQZMNVNMU-ABCDUJAMSA-N (2s)-2-[[(2s)-2-[[(2s)-1-[2-[[(2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]a Chemical compound C([C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C(C)C)C1=CC=C(O)C=C1 QMLXCJQZMNVNMU-ABCDUJAMSA-N 0.000 description 1
- QTNCVVIHEYTVBY-ZXDAYAIVSA-N (2s,3s)-2-[[(2s)-1-[(2s)-2-[[(2s)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoic acid Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)CN)CC1=CC=CC=C1 QTNCVVIHEYTVBY-ZXDAYAIVSA-N 0.000 description 1
- ZQOILFFBJUNGRA-NMVUUJPQSA-N (4s)-4-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-[(2s)-2-[[(2s,3s)-1-[(2s)-2-[[(1s)-1-carboxy-2-(4-hydroxyphenyl)ethyl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-5-oxopentanoic acid Chemical compound N([C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)C(C)C ZQOILFFBJUNGRA-NMVUUJPQSA-N 0.000 description 1
- ZBLQIYPCUWZSRZ-QEJZJMRPSA-N Ala-Phe-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CC=CC=C1 ZBLQIYPCUWZSRZ-QEJZJMRPSA-N 0.000 description 1
- BTRULDJUUVGRNE-DCAQKATOSA-N Ala-Pro-Lys Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O BTRULDJUUVGRNE-DCAQKATOSA-N 0.000 description 1
- GIQZFLZPSASIEJ-UHFFFAOYSA-N Ala-Val-Pro-Tyr-Pro-Gln-Arg Natural products CC(N)C(=O)NC(C(C)C)C(=O)N1CCCC1C(=O)NC(C(=O)N1C(CCC1)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(O)=O)CC1=CC=C(O)C=C1 GIQZFLZPSASIEJ-UHFFFAOYSA-N 0.000 description 1
- RRGPUNYIPJXJBU-GUBZILKMSA-N Arg-Asp-Met Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O RRGPUNYIPJXJBU-GUBZILKMSA-N 0.000 description 1
- NKBQZKVMKJJDLX-SRVKXCTJSA-N Arg-Glu-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NKBQZKVMKJJDLX-SRVKXCTJSA-N 0.000 description 1
- MYCSPQIARXTUTP-SRVKXCTJSA-N Asn-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC(=O)N)N MYCSPQIARXTUTP-SRVKXCTJSA-N 0.000 description 1
- MKJBPDLENBUHQU-CIUDSAMLSA-N Asn-Ser-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O MKJBPDLENBUHQU-CIUDSAMLSA-N 0.000 description 1
- GHWWTICYPDKPTE-NGZCFLSTSA-N Asn-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)N)N GHWWTICYPDKPTE-NGZCFLSTSA-N 0.000 description 1
- XMKXONRMGJXCJV-LAEOZQHASA-N Asp-Val-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O XMKXONRMGJXCJV-LAEOZQHASA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100098985 Caenorhabditis elegans cct-3 gene Proteins 0.000 description 1
- 101800003171 Casoparan Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- NPTGGVQJYRSMCM-GLLZPBPUSA-N Gln-Gln-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NPTGGVQJYRSMCM-GLLZPBPUSA-N 0.000 description 1
- KPNWAJMEMRCLAL-GUBZILKMSA-N Gln-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)N)N KPNWAJMEMRCLAL-GUBZILKMSA-N 0.000 description 1
- HUWSBFYAGXCXKC-CIUDSAMLSA-N Glu-Ala-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(O)=O HUWSBFYAGXCXKC-CIUDSAMLSA-N 0.000 description 1
- XXCDTYBVGMPIOA-FXQIFTODSA-N Glu-Asp-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O XXCDTYBVGMPIOA-FXQIFTODSA-N 0.000 description 1
- HNVFSTLPVJWIDV-CIUDSAMLSA-N Glu-Glu-Gln Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HNVFSTLPVJWIDV-CIUDSAMLSA-N 0.000 description 1
- MUSGDMDGNGXULI-DCAQKATOSA-N Glu-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O MUSGDMDGNGXULI-DCAQKATOSA-N 0.000 description 1
- IQACOVZVOMVILH-FXQIFTODSA-N Glu-Glu-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O IQACOVZVOMVILH-FXQIFTODSA-N 0.000 description 1
- STVHDEHTKFXBJQ-LAEOZQHASA-N Gly-Glu-Ile Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O STVHDEHTKFXBJQ-LAEOZQHASA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- JUIOPCXACJLRJK-AVGNSLFASA-N His-Lys-Glu Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N JUIOPCXACJLRJK-AVGNSLFASA-N 0.000 description 1
- LNJLOZYNZFGJMM-DEQVHRJGSA-N Ile-His-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@@H]2C(=O)O)N LNJLOZYNZFGJMM-DEQVHRJGSA-N 0.000 description 1
- FQYQMFCIJNWDQZ-CYDGBPFRSA-N Ile-Pro-Pro Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 FQYQMFCIJNWDQZ-CYDGBPFRSA-N 0.000 description 1
- PZWBBXHHUSIGKH-OSUNSFLBSA-N Ile-Thr-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N PZWBBXHHUSIGKH-OSUNSFLBSA-N 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- HGCNKOLVKRAVHD-UHFFFAOYSA-N L-Met-L-Phe Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 HGCNKOLVKRAVHD-UHFFFAOYSA-N 0.000 description 1
- ZYLJULGXQDNXDK-GUBZILKMSA-N Leu-Gln-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O ZYLJULGXQDNXDK-GUBZILKMSA-N 0.000 description 1
- CQGSYZCULZMEDE-UHFFFAOYSA-N Leu-Gln-Pro Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)N1CCCC1C(O)=O CQGSYZCULZMEDE-UHFFFAOYSA-N 0.000 description 1
- JNDYEOUZBLOVOF-AVGNSLFASA-N Leu-Leu-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O JNDYEOUZBLOVOF-AVGNSLFASA-N 0.000 description 1
- LCNASHSOFMRYFO-WDCWCFNPSA-N Leu-Thr-Gln Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O LCNASHSOFMRYFO-WDCWCFNPSA-N 0.000 description 1
- QWWPYKKLXWOITQ-VOAKCMCISA-N Leu-Thr-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(C)C QWWPYKKLXWOITQ-VOAKCMCISA-N 0.000 description 1
- BQVUABVGYYSDCJ-ZFWWWQNUSA-N Leu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-ZFWWWQNUSA-N 0.000 description 1
- QBEPTBMRQALPEV-MNXVOIDGSA-N Lys-Ile-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCCCN QBEPTBMRQALPEV-MNXVOIDGSA-N 0.000 description 1
- IEIHKHYMBIYQTH-YESZJQIVSA-N Lys-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CCCCN)N)C(=O)O IEIHKHYMBIYQTH-YESZJQIVSA-N 0.000 description 1
- NYTDJEZBAAFLLG-IHRRRGAJSA-N Lys-Val-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O NYTDJEZBAAFLLG-IHRRRGAJSA-N 0.000 description 1
- BMHIFARYXOJDLD-WPRPVWTQSA-N Met-Gly-Val Chemical compound [H]N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O BMHIFARYXOJDLD-WPRPVWTQSA-N 0.000 description 1
- MQASRXPTQJJNFM-JYJNAYRXSA-N Met-Pro-Phe Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MQASRXPTQJJNFM-JYJNAYRXSA-N 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- BQVUABVGYYSDCJ-UHFFFAOYSA-N Nalpha-L-Leucyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-UHFFFAOYSA-N 0.000 description 1
- 108010093625 Opioid Peptides Proteins 0.000 description 1
- 102000001490 Opioid Peptides Human genes 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- AJOKKVTWEMXZHC-DRZSPHRISA-N Phe-Ala-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 AJOKKVTWEMXZHC-DRZSPHRISA-N 0.000 description 1
- OPEVYHFJXLCCRT-AVGNSLFASA-N Phe-Gln-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O OPEVYHFJXLCCRT-AVGNSLFASA-N 0.000 description 1
- RSPUIENXSJYZQO-JYJNAYRXSA-N Phe-Leu-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 RSPUIENXSJYZQO-JYJNAYRXSA-N 0.000 description 1
- ZJPGOXWRFNKIQL-JYJNAYRXSA-N Phe-Pro-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=CC=C1 ZJPGOXWRFNKIQL-JYJNAYRXSA-N 0.000 description 1
- XNQMZHLAYFWSGJ-HTUGSXCWSA-N Phe-Thr-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O XNQMZHLAYFWSGJ-HTUGSXCWSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- ODPIUQVTULPQEP-CIUDSAMLSA-N Pro-Gln-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]1CCCN1 ODPIUQVTULPQEP-CIUDSAMLSA-N 0.000 description 1
- VPEVBAUSTBWQHN-NHCYSSNCSA-N Pro-Glu-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O VPEVBAUSTBWQHN-NHCYSSNCSA-N 0.000 description 1
- BWCZJGJKOFUUCN-ZPFDUUQYSA-N Pro-Ile-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O BWCZJGJKOFUUCN-ZPFDUUQYSA-N 0.000 description 1
- FJLODLCIOJUDRG-PYJNHQTQSA-N Pro-Ile-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@@H]2CCCN2 FJLODLCIOJUDRG-PYJNHQTQSA-N 0.000 description 1
- FHJQROWZEJFZPO-SRVKXCTJSA-N Pro-Val-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 FHJQROWZEJFZPO-SRVKXCTJSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- FMDHKPRACUXATF-ACZMJKKPSA-N Ser-Gln-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O FMDHKPRACUXATF-ACZMJKKPSA-N 0.000 description 1
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 1
- XQJCEKXQUJQNNK-ZLUOBGJFSA-N Ser-Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O XQJCEKXQUJQNNK-ZLUOBGJFSA-N 0.000 description 1
- FRPNVPKQVFHSQY-BPUTZDHNSA-N Ser-Trp-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CO)N FRPNVPKQVFHSQY-BPUTZDHNSA-N 0.000 description 1
- YEDSOSIKVUMIJE-DCAQKATOSA-N Ser-Val-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O YEDSOSIKVUMIJE-DCAQKATOSA-N 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- LIXBDERDAGNVAV-XKBZYTNZSA-N Thr-Gln-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O LIXBDERDAGNVAV-XKBZYTNZSA-N 0.000 description 1
- SBYQHZCMVSPQCS-RCWTZXSCSA-N Thr-Val-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCSC)C(O)=O SBYQHZCMVSPQCS-RCWTZXSCSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- AGKDVLSDNSTLFA-UMNHJUIQSA-N Val-Gln-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N AGKDVLSDNSTLFA-UMNHJUIQSA-N 0.000 description 1
- OQWNEUXPKHIEJO-NRPADANISA-N Val-Glu-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)O)N OQWNEUXPKHIEJO-NRPADANISA-N 0.000 description 1
- RYQUMYBMOJYYDK-NHCYSSNCSA-N Val-Pro-Glu Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)O)N RYQUMYBMOJYYDK-NHCYSSNCSA-N 0.000 description 1
- DOFAQXCYFQKSHT-SRVKXCTJSA-N Val-Pro-Pro Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DOFAQXCYFQKSHT-SRVKXCTJSA-N 0.000 description 1
- PMKQKNBISAOSRI-XHSDSOJGSA-N Val-Tyr-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@@H]2C(=O)O)N PMKQKNBISAOSRI-XHSDSOJGSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002605 anti-dotal effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- 108010060144 beta-casokinin 10 Proteins 0.000 description 1
- 108010020596 beta-casomorphin 5 Proteins 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229940021722 caseins Drugs 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 108010031424 isoleucyl-prolyl-proline Proteins 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 108010009298 lysylglutamic acid Proteins 0.000 description 1
- 108010017391 lysylvaline Proteins 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108010068488 methionylphenylalanine Proteins 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003399 opiate peptide Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 108010029020 prolylglycine Proteins 0.000 description 1
- 108010090894 prolylleucine Proteins 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 108010030651 valyl-glutamyl-prolyl-isoleucyl-prolyl-tyrosine Proteins 0.000 description 1
- 108010015385 valyl-prolyl-proline Proteins 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4732—Casein
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to albumen field, and in particular to its amino acid sequence of a kind of biologically active polypeptide QPVLGPVRGP and its preparation method and application, biologically active polypeptide QPVLGPVRGP is Gln Pro Val Leu Gly Pro Val Arg Gly Pro.By the experiment of ion vitro immunization function point analysis, internal Antisenility Experiment, demonstrating polypeptide QPVLGPVRGP has preferable immunoloregulation function and activity of fighting against senium, on the one hand, the biologically active polypeptide QPVLGPVRGP of the present invention can strengthen the in-vitro multiplication ability of lymphocyte and macrophage, the ability that body resists extraneous pathogenic infection is improved, reduces body incidence；On the other hand, the vigor of internal anti-peroxidation enzyme system can be improved, strengthen the function of body resistance external source sexual stimulus, so as to reduce organism aging process, aging and sick probability, exploitation is of great significance with immunoloregulation function, the food of anti-senescence function, health products and medicine tool.
Description
Technical field
The present invention relates to albumen field, more particularly, to a kind of biologically active polypeptide QPVLGPVRGP and preparation method thereof and
Using.
Background technology
During cow's milk is through lactobacillus-fermented, a part of protein in cow's milk is metabolized by lactic acid bacteria to be utilized, concurrently
A series of biochemical reactions have been given birth to, protein is changed into polypeptide or free amino acid, is digested or passes through
The absorption and transport of intestinal epithelial cell is directly entered the blood circulation of human body.In these polypeptides, some is with special
Physiological function, is referred to as " biologically active peptide ".
It is particularly important that safe biologically active peptide is found in natural food source.In recent years, it has been found that some foods
The polypeptides matter in thing source has good bioactivity, such as corn small peptide, soybean peptide, cow's milk polypeptide.These polypeptides can
To be obtained by number of ways such as microbial fermentation, digestion enzymolysis, and biologically active polypeptide is by 2~20 mostly
Amino acid residue forms, and molecular weight is less than 6000Da, contains a certain amount of hydrophobic amino acid, aromatic amino acid.
Immune-active peptides are to obtain and prove that one kind biology of its physiological activity is living from breast first after opioid peptides discovery
Property polypeptide.Jolles in 1981 et al. has found first, using trypsin hydrolysis people lactoprotein, can obtain an amino acid sequence
The hexapeptide of Val-Glu-Pro-Ile-Pro-Tyr is classified as, experiment in vitro proves that the peptide can strengthen Turnover of Mouse Peritoneal Macrophages pair
The phagocytosis of sheep red blood cell (SRBC).Migliore-Samour et al. has found the hexapeptide Thr-Thr-Met-Pro- from casein
Leu-Trp can stimulate phagocytosis and enhancing of the sheep erythrocyte to mouse peritoneal macrophages for kerekou pneumonia primary
The resistance of bacterium.Li Su duckweeds et al. find rat peritoneal macrophages with newborn source immunomodulatory peptides (PGPIPN) the feeding rat of synthesis
Phagocytosis and the relevant immunoloregulation function of red blood cell have significant enhancing.
Research shows that immune-active peptides can not only strengthen immunity of organisms, stimulates the propagation of body lymphocyte, enhancing
The phagocytic function of macrophage, promotes the release of cell factor, improves the ability that body resists extraneous pathogenic infection, reduce machine
Body incidence, and the immunological rejection of body will not be caused.
Aging is a natural phenomena, and process is often accompanied by the change of antioxidant levels, organ-tissue, immune factor, its
The change of complexity, the trend that such as proinflammatory cytokine IL-6, IL-4, TNF-α presentation increase, IL-6 occur for middle cell factor
It is all considered to play an important role in the generating process of geriatric disease with TNF-a.With science of heredity and molecular biology
Development, the research of biological decay mechanism achieve gratifying progress.Researcher by using some model organisms, as mouse,
The term single gene mutating experiment of drosophila and C. Elegans Automatic Screening etc., it is found that some genes can dramatically increase service lifes of these organisms and reach
As many as 6 times.
Anti-aging peptide in terms of physiological function there is amino acid cannot compare excellent as a kind of emerging antidotal agent
Gesture, it can produce promotion or inhibitory action to the enzyme in organism, improve absorption and the profit to mineral matter and other nutrients
With, removing interior free yl, the resistance to oxidation of enhancing body itself, to slow down aging.Therefore, the nutrition and health care of biologically active peptide
Effect has become the emphasis of domestic and foreign scholars' subject study.Qiu Juan et al. pass through experimental studies have found that, milk-derived bioactive micro peptide
Life span of drosophila melanogaster can effectively be extended, delay its aging, and also there is preferable antioxidation, thus it is speculated that be probably wherein to be rich in coloured glaze
Base peptides.SOD vigor in serum, reduces its lipid in discovery bovine colostrum extract energy conspicuousness raising the elderly's body such as the brightness in week
Peroxide and enhancing body resistance to oxidation, have certain anti-senescence function.
The research on biologically active polypeptide has much at present, for example Chinese patent CN105254738A discloses one kind and comes
The milk-derived biologically active polypeptide DELQDKIH of beta-casein is come from, Chinese patent CN105254739A discloses one kind and derives from
The milk-derived biologically active polypeptide GTQYTD of α s1- caseins, Chinese patent CN105254740A, which are disclosed, a kind of derives from α s2-
The milk-derived biologically active polypeptide NQFYQKF of casein.
The content of the invention
It is an object of the invention to provide a kind of biologically active polypeptide QPVLGPVRGP and its preparation method and application.
The purpose of the present invention can be achieved through the following technical solutions：
First aspect present invention, there is provided a kind of biologically active polypeptide QPVLGPVRGP, its amino acid sequence are Gln-Pro-
Val-Leu-Gly-Pro-Val-Arg-Gly-Pro, such as SEQ ID NO：Shown in 1.
Preferably, the biologically active polypeptide is milk-derived.Beta-casein is derive specifically from, and is beta-casein variation
The amino acid residue that A1 is the 195th~204.1 amino acid sequence of beta-casein modification A such as SEQ ID NO：Shown in 3.
The amino acid sequence of beta-casein and corresponding nucleotides sequence are classified as existing technology, encoding ss-casein modification A 1
The biologically active polypeptide QPVLGPVRGP of the nucleotide fragments energy encoding mature of 195th~204 amino acids residue.
Preferably, the biologically active polypeptide has immunoloregulation function and anti-senescence function.
Second aspect of the present invention, there is provided encode the nucleotide fragments of the biologically active polypeptide QPVLGPVRGP, its sequence
It is classified as：5 '-cag cct gta ctc ggt cct gtc cgg gga cct-3 ', such as SEQ ID NO：Shown in 2.
Third aspect present invention, there is provided the preparation method of the biologically active polypeptide QPVLGPVRGP, can pass through base
Because the method for engineering is artificial synthesized, can be directly obtained from dairy products by the method isolated and purified, can direct passing through
Learn synthetically prepared.
Fourth aspect present invention, there is provided the biologically active polypeptide QPVLGPVRGP has immunoloregulation function in preparation
Food, health products, the application in medicine or cosmetics.
Fifth aspect present invention, there is provided the biologically active polypeptide QPVLGPVRGP is being prepared with anti-senescence function
Application in food, health products or medicine.
Sixth aspect present invention, there is provided the biologically active polypeptide QPVLGPVRGP is being prepared while had immunological regulation
Application in the food of function and anti-senescence function, health products or medicine.
Specifically, biologically active polypeptide QPVLGPVRGP of the invention, which can be used for preparing, reduces free radical to skin wound
The harmful medicine of cosmetics, preparation with immunological regulation and/or anti-aging；And due to the biologically active polypeptide of the present invention
Product after QPVLGPVRGP is degraded by intestines and stomach still has bioactivity, therefore can be also used for preparing the food such as Yoghourt
Product, the health products for adjusting immunity, and the oral medicine being used to prepare with immunological regulation and/or anti-aging.
Seventh aspect present invention, there is provided a kind of immunological regulation product, including the biologically active polypeptide QPVLGPVRGP
Or the derivative of the biologically active polypeptide QPVLGPVRGP；The immunological regulation product includes immunological regulation food, is immunized
Adjust health products, immunoregulation medicament or immunological regulation cosmetics；The derivative of the biologically active polypeptide QPVLGPVRGP, is
Refer on the amino acid side groups of biologically active polypeptide QPVLGPVRGP, aminoterminal or c-terminus carry out hydroxylating, carboxylated,
Be carbonylated, methylate, acetylation, phosphorylation, the modification such as esterification or glycosylation, obtained polypeptide derivative.
Eighth aspect present invention, there is provided a kind of anti-aging product, including the biologically active polypeptide QPVLGPVRGP or
The derivative of the biologically active polypeptide QPVLGPVRGP；The anti-aging product includes antisenility cistanche food, anti-ageing healthcare
Product or antiaging agent；The derivative of the biologically active polypeptide QPVLGPVRGP, refers in biologically active polypeptide
On the amino acid side groups of QPVLGPVRGP, aminoterminal or c-terminus carry out hydroxylating, carboxylated, be carbonylated, methylate, second
Acylation, phosphorylation, esterification or glycosylation etc. are modified, obtained polypeptide derivative.
Ninth aspect present invention, there is provided product a kind of while that there is immunoloregulation function and anti-senescence function, including
The derivative of the biologically active polypeptide QPVLGPVRGP or described biologically active polypeptides QPVLGPVRGP；With immunological regulation work(
It can include food, health products or medicine with the product of anti-senescence function；The derivative of the biologically active polypeptide QPVLGPVRGP,
Refer on the amino acid side groups of biologically active polypeptide QPVLGPVRGP, aminoterminal or c-terminus carry out hydroxylating, carboxyl
Change, be carbonylated, methylating, acetylation, phosphorylation, the modification such as esterification or glycosylation, obtained polypeptide derivative.
Biologically active polypeptide QPVLGPVRGP's of the present invention has the beneficial effect that：The milk-derived biologically active polypeptide of the present invention
QPVLGPVRGP has preferable adjusting immunity of organisms activity and activity of fighting against senium；On the one hand, bioactivity of the invention is more
Peptide QPVLGPVRGP can strengthen the in-vitro multiplication ability of lymphocyte and macrophage, improve body and resist extraneous cause of disease body-sensing
The ability of dye, reduces body incidence；On the other hand, it is possible to increase the vigor of internal anti-peroxidation enzyme system, enhancing body resistance
The function of external source sexual stimulus, so as to reduce organism aging process, aging and sick probability, with immunoloregulation function and resists exploitation
Dairy products and the health products tool of aging function are of great significance.
Brief description of the drawings
Fig. 1：Mass chromatography extraction figure (m/z=510.7985)；
Fig. 2：Mass-to-charge ratio is the second order ms figure of 510.7985 fragment；
Fig. 3：Each group experimental animal mouse spleen situation of change；
(a) it is low dosage gavage group mouse spleen organization chart；(b) it is high dose gavage group mouse spleen organization chart；(c) it is
Naive mice spleen tissue；(d) it is animal model group mouse spleen organization chart；
Fig. 4：Each group mice serum IL-6 changes table；
Fig. 5：Each group mice serum TNF-α changes table.
Embodiment
Before specific embodiments of the present invention are further described, it should be appreciated that protection scope of the present invention is not limited to down
State specific specific embodiment；It is also understood that the term used in the embodiment of the present invention is specific specific in order to describe
Embodiment, the protection domain being not intended to be limiting of the invention.
When embodiment provides number range, it should be appreciated that except non-invention is otherwise noted, two ends of each number range
Any one numerical value can be selected between point and two endpoints.Unless otherwise defined, in the present invention all technologies for using and
Scientific terminology is identical with the normally understood meaning of those skilled in the art of the present technique.Except used in embodiment specific method, equipment,
Outside material, according to grasp of the those skilled in the art to the prior art and the record of the present invention, it can also use and this
Any method, equipment and the material of the similar or equivalent prior art of method, equipment described in inventive embodiments, material come real
The existing present invention.
Unless otherwise stated, disclosed in this invention experimental method, detection method, preparation method using this technology lead
Molecular biology, biochemistry, chromatin Structure and the analysis of domain routine, analytical chemistry, cell culture, recombinant DNA technology and
The routine techniques of association area.These technologies existing perfect explanation in the prior art, for details, reference can be made to Sambrook etc.
MOLECULAR CLONING：A LABORATORY MANUAL, Second edition, Cold Spring Harbor
Laboratory Press, 1989and Third edition, 2001；Ausubel etc., CURRENT PROTOCOLS IN
MOLECULAR BIOLOGY, John Wiley＆Sons, New York, 1987and periodic updates；the
Series METHODS IN ENZYMOLOGY, Academic Press, San Diego；Wolffe, CHROMATIN
STRUCTURE AND FUNCTION, Third edition, Academic Press, San Diego, 1998；METHODS IN
ENZYMOLOGY, Vol.304, Chromatin (P.M.Wassarman and A.P.Wolffe, eds.), Academic
Press, San Diego, 1999；With METHODS IN MOLECULAR BIOLOGY, Vol.119, Chromatin
Protocols (P.B.Becker, ed.) Humana Press, Totowa, 1999 etc..
The present invention is described in detail with specific embodiment below in conjunction with the accompanying drawings.
1 active peptide QPVLGPVRGP's of embodiment is artificial synthesized
First, the synthesis of biologically active peptide
1. RINK resin 3g (substitution value 0.3mmol/g) are weighed in the reactor of 150ml, with the dichloromethane of 50ml
(DCM) soak.
2. 2 it is small when after, wash resin with nitrogen-dimethylformamide (DMF) of 3 times of resin volumes, then drain, so
It is repeated four times, resin is drained rear stand-by.
3. a certain amount of 20% piperidines (piperidines/DMF=1 is added into reactor:4,v:V), it is placed on decolorization swinging table and shakes
20min is shaken, the Fmoc blocking groups on resin are sloughed with this.Washed four times with the DMF of 3 times of resin volumes after having taken off protection,
Then drain.
4. take the detection of a small amount of resin ninhydrin (nine well ninhydrins) method (each two drop of inspection A, inspection B, 100 DEG C of reactions
1min), resin has color, illustrates to be deprotected successfully.
5. weigh amino acid Gln in right amount and 1- hydroxyls-benzene a pair of horses going side by side triazole (HOBT) is in right amount in the centrifuge tube of 50ml, addition
The DMF of 20ml is dissolved, and then adds the N of 3ml, and N diisopropylcarbodiimide (DIC) vibration shakes up 1min, treats that solution is clear
It is added to after clear in reactor, then reactor is placed in 30 DEG C of shaking table and is reacted.
6. 2 it is small when after, with a certain amount of acetic anhydride end socket (acetic anhydride:DIEA:DCM=1:1:2,v:v:V) half an hour,
Then washed four times, drained stand-by with the DMF of 3 times of resin volumes.
7. a certain amount of 20% piperidines (piperidines/DMF=1 is added into reactor:4, v:V), it is placed on decolorization swinging table and shakes
20min is shaken, the Fmoc blocking groups on resin are sloughed with this.Washed four times with DMF after having taken off protection, then drained.
8. take the detection of a small amount of resin ninhydrin (nine well ninhydrins) method (each two drop of inspection A, inspection B, 100 DEG C of reactions
1min), resin has color, illustrates to be deprotected successfully.
9. weighing second amino acid next in right amount and HOBT being in right amount in the centrifuge tube of 50ml, the DMF generals of 25ml are added
It is dissolved, and the DIC vibrations for then adding 2.5ml shake up 1min, are added to after solution clarification in reactor, then by reactor
It is placed in 30 DEG C of shaking table and reacts.
10. 1 it is small when after, take a small amount of resin to detect, (each two drop of inspection A, inspection B, 100 DEG C of reactions detected with ninhydrin method
1min), if resin is colourless, illustrate that the reaction was complete；If resin has color, illustrate that condensation is incomplete, the reaction was continued.
11. after complete reaction, washing resin four times with DMF, then drain, a certain amount of 20% is added into reactor
Piperidines (piperidines/DMF=1:4,v:V), it is placed on decolorization swinging table and rocks 20min, the Fmoc protection groups on resin is sloughed with this
Group.Washed four times with DMF after having taken off protection, then drain whether detection protection sloughs.
12. amino acid Pro, Val, Leu, Gly, Pro, Val, Arg, Gly and Pro are connected successively according to step 9-11.
13. after last amino acid is connected, protection is sloughed, is washed four times with DMF, is then taken out resin with methanol
It is dry.Then with 95 cutting liquid (trifluoroacetic acids:1,2 dithioglycols:3, isopropyl base silane:Water=95:2:2:1, v:v:V) by polypeptide
Cut down from resin (every gram of resin adds 10ml cutting liquids), and with ice ether (cutting liquid：Ether=1:9,v:V) centrifugation is heavy
Drop four times.
So far, artificial synthesized biologically active peptide QPVLGPVRGP.
2nd, the confirmation of biologically active peptide
1) UPLC is analyzed
UPLC conditions are as follows：
Instrument：Waters ACQUITY UPLC ultra high efficiency liquid phase-electron spray-level Four bar-time of-flight mass spectrometer
Chromatographic column specification：BEH C18 chromatographic columns
Flow velocity：0.4mL/min
Temperature：50℃
Ultraviolet detection wavelength：210nm
Sample size：2μL
Gradient condition：A liquid：Water containing 0.1% formic acid (v/v), B liquid：Acetonitrile containing 0.1% formic acid (v/v)
2) mass spectral analysis
Mass Spectrometry Conditions are as follows：
Ionic means：ES+
Mass range (m/z)：100-1000
Capillary voltage (Capillary) (kV)：3.0
Sampling spiroid (V)：35.0
Ion source temperature (DEG C)：115
Remove solvent temperature (DEG C)：350
Go solvent stream (L/hr)：700.0
Collision energy (eV)：4.0
Sweep time (sec)：0.25
Interior sweep time (sec)：0.02
According to above analysis method, using ultra high efficiency liquid phase-electron spray-level Four bar-flight time mass spectrum, to bioactivity
Peptide QPVLGPVRGP carries out chromatography and mass spectral analysis, its mass chromatography extraction figure is as shown in Figure 1, extract the two level matter at this peak
For spectrogram as shown in Fig. 2, the polypeptide mass-to-charge ratio that can obtain this peak is 510.7985Da, retention time is 31.1min.
3) result
Calculated by Mascot software analysis, the fragment sequence for obtaining mass-to-charge ratio 510.7985Da is Gln-Pro-Val-
Leu-Gly-Pro-Val-Arg-Gly-Pro (QPVLGPVRGP), is denoted as SEQ ID NO：1.The fragment and beta-casein variation
The residue sequence that A1 is the 195th~204 is corresponding, and the GenBank of beta-casein amino acid sequence numbering is AAA30431.1, sequence
Row are shown in SEQ ID NO：3.
The adjusting immunity of organisms activity experiment of 2 biologically active peptide of embodiment
First, the vitro lymphocyte proliferation capacity experimental 1. of mtt assay measure biologically active polypeptide QPVLGPVRGP tests material
Material and instrument：
Reagent and material：Experimental animal balb/c mouse (male 6-8 week old, Shanghai Communications University's agricultural and biological institute
Animal experimental center)；The milk-derived biologically active polypeptide QPVLGPVRGP that embodiment 1 obtains；(the purchase of mouse lymphocyte extracting solution
From Suo Laibao companies)；RPMI1640 culture mediums (are purchased from GIBCO companies)；3- (4,5- dimethylthiazole -2) -2,5- diphenyl four
Nitrogen azoles bromide (MTT, purchased from Amresco companies)；ConA (ConA, purchased from Sigma companies)；Bovine serum albumin(BSA)
(BSA, purchased from Genebase companies)；Pepsin (is purchased from Sigma companies)；Pancreatin (Corolase PP, purchased from AB companies).
Instrument and equipment：LRH-250F biochemical cultivation cases, Shanghai perseverance Science and Technology Ltd.；GL-22M high speed freezing centrifuges,
Shanghai Lu Xiang instrument centrifuges Instrument Ltd.；Hera cell 150CO2 incubators, Heraeus companies；Dragon
Wellscan MK3 microplate reader, Labsystems companies；ALPHA 1-2-LD vacuum freeze driers, Christ companies；Superelevation
Effect liquid phase chromatogram-quadrupole rod time of-flight mass spectrometer, waters companies.
2. experimental method：
Mouse spleen is taken under aseptic condition, mouse lymphocyte is extracted with lymphocyte extracting solution, carries out Yuan Dynasty's culture.With
Cell density is adjusted to 2.5 × 10 by complete RPMI1640 nutrient solutions6A/mL.Sequentially added in 96 porocyte culture plates：
100 μ L mouse lymphocyte suspensions, 100 μ L RPMI1640 complete culture solutions, 20 μ L ConAs, 100 μ L samples.In addition,
Blank control group (PBS of pH7.2~7.4,3mol/L) and negative control group (500 μ g/mL BSA) are set, and research shows that its is right
Do not influenced in vitro lymphocyte proliferation.Every group of 3 parallel laboratory test samples.In 5%CO2After 68h being cultivated in 37 DEG C of incubators,
20 μ L MTT are added under aseptic condition per hole, continue to cultivate 4h, careful abandoning supernatant, 100 μ L dimethyl sulfoxide (DMSO)s are added per hole,
37 DEG C of biochemical cultivation cases hatch 10min, shake up, light absorption value is measured at 570nm with microplate reader.
Vitro lymphocyte proliferation ability represents that computational methods are as follows with stimulus index：
In formula：A1For blank control at the 570nm under light absorption value；A2For negative control group at the 570nm under extinction
Value, A3For experimental group at the 570nm under light absorption value.
3. experimental result and analysis：
Influences of the 1 biologically active polypeptide QPVLGPVRGP of table to vitro lymphocyte proliferation
| Experiment packet | Stimulus index SI |
| Negative control group | 1 |
| QPVLGPVRGP | 1.180±0.013* |
Note：* labelled notation is compared with negative control, there is significant difference (P ＜ 0.05).
Experimental result is shown in Table 1.As shown in Table 1, it is 100 μ g/mL's in the mass concentration of biologically active peptide QPVLGPVRGP
Under the conditions of, the stimulus index of milk-derived biologically active peptide QPVLGPVRGP is more than BSA, illustrates that QPVLGPVRGP to a certain extent can
Stimulate the propagation of external mouse lymphocyte.And the stimulus index of QPVLGPVRGP has reached 1.180, and negative control group tool
There were significant differences (P<0.05).Therefore, it can be assumed that active peptides QPVLGPVRGP, which has, remarkably promotes mouse lymphocyte
The ability of propagation, can be used as a kind of health products or additive to eat, it is possible to increase the immunity of animal and human body.
2nd, macrophages in vitro multiplication capacity experiment 1) the experiment examination of mtt assay measure biologically active polypeptide QPVLGPVRGP
Agent and instrument
Reagent：Experimental animal balb/c mouse (male 6-8 week old) Shanghai Communications University agricultural and biological institute animal reality
Test center；The milk-derived biologically active polypeptide QPVLGPVRGP that embodiment 1 obtains；3- (4,5- dimethylthiazole -2) -2,5- bis-
Phenyl tetrazole bromide (MTT) Amresco companies；LPS (lipopolysaccharides) Sigma companies；Bovine serum albumin(BSA) (Bovine Serum
Albumin, BSA) Genebase companies；Three lysates, the water containing 10%SDS, 5% isobutanol and 0.012mol/L HCl
Solution.
Instrument and equipment：LRH-250F biochemical cultivation cases Shanghai perseverance Science and Technology Ltd.；On GL-22M high speed freezing centrifuges
Hai Luxiang instrument centrifuges Instrument Ltd.；Hera cell 150CO2Incubator Heraeus companies；Dragon Wellscan
MK3 microplate reader Labsystems companies.
2) test method：
2% (w/w) the sterilizing starch solutions of balb/c mouse peritoneals injection 2ml, continuous injection three days, last time is injected
24 it is small when after break neck put to death.Skin of abdomen is peelled off, 4 DEG C of phosphate buffers (PBS) is drawn with syringe and rinses abdominal cavity repeatedly, from
After heart pipe collects flushing liquor, supernatant is abandoned in centrifugation (1000rpm, 4 DEG C) after ten minutes, (is contained with 4 DEG C of RPMI1640 complete culture solutions
10%FBS) wash twice, cell viability examination is done in the dyeing of 0.2% trypan blue solution, confirms the vibrant macrophage collected
Account for more than 95%.After cell counting count board reading, adjustment cell concentration to suitable concentration.
It will blow and beat to the cell suspension to suspend completely and added 96 porocyte culture plates, 37 DEG C, 5%CO with suitable volumes2
After when culture 4 is small under environment, liquid in hole is abandoned in suction, and cell culture plate well is carefully cleaned with 37 DEG C of RPMI1640 complete culture solutions
Bottom, washes away not adherent cell and cell fragment, obtains adherent peritoneal macrophage after purification.0.2ml is added per hole
RPMI1640 complete mediums, experiment add after being dissolved in culture medium in advance with small peptide sample and LPS, start cell culture.
After obtaining adherent peritoneal macrophage after purification, experimental group adds dissolved with biologically active polypeptide LPLP per hole
The 200 μ l/ holes of RPMI1640 complete culture solutions (10%FBS) of (1mg/ml), continuously cultivate 48h；Negative control group is per hole solubilization
Solution has the 200 μ l/ holes of RPMI1640 complete culture solutions (10%FBS) of BSA (500 μ g/mL)；Blank group addition RPMI1640 is complete
200 μ l/ holes of nutrient solution (10%FBS), continuously cultivate 48h.Also, experimental group, negative control group and blank group are set just respectively again
Often group and inflammation group；Inflammation group adds LPS to final concentration of 100ng/ml when 24h is arrived in culture；Normal group is not added with LPS；And
Normal group and inflammation group add 20 μ l/ holes of 5%MTT in 44h；Cell culture, which reaches, adds the three molten of 100 μ l/ holes after 48h
Solution liquid is to terminate culture, after dissolving overnight, surveys the absorbance (OD570) in each hole with microplate reader under wavelength 570nm, growth refers to
The calculation formula of number (Growth Indices) is as follows：
Wherein, blank nutrient solution is the RPMI1640 complete culture solutions containing 10%FBS.
3) experimental result and analysis
The influence that 2 biologically active polypeptide QPVLGPVRGP of table breeds macrophages in vitro
| Experiment packet | Normal group GI | Inflammation group GI |
| Negative control group | 1 | 1 |
| QPVLGPVRGP(1mg/ml) | 1.0842±0.0523** | 1.129±0.0633** |
Note：* represent compared with negative control, there is significant difference (P ＜ 0.05)；* represent compared with negative control group,
There is significant difference (P ＜ 0.01)
Experimental result is shown in Table 2, as shown in Table 2, under conditions of 1mg/ml biologically active polypeptides QPVLGPVRGP is added, just
Often the macrophage of group and inflammation group has propagation.And compared with negative control group, there is significant difference (P ＜ 0.01).
Illustrate that biologically active polypeptide QPVLGPVRGP has significant proliferation function to macrophages in vitro.
The activity of fighting against senium experiment of 3 biologically active peptide of embodiment
First, experiments of the biologically active polypeptide QPVLGPVRGP to internal spleen tissue structure function
1. experiment reagent and instrument：
Reagent：Experimental animal ICR mouse (male 5 week old), Shanghai City Experimental Animal Center；D-gal, Chinese medicines group chemistry
Reagent Co., Ltd；Paraformaldehyde, Sinopharm Chemical Reagent Co., Ltd.；Sodium chloride, the limited public affairs of Chinese medicines group chemical reagent
Department；The milk-derived biologically active polypeptide QPVLGPVRGP that embodiment 1 obtains.
Instrument and equipment：The ultra-clean water of CM-230 types mole, Shanghai Moller scientific instrument Co., Ltd；Mi Libo Millipore
MILLEX GP0.22 μm filter membranes, Millipore Corp. of the U.S.；GL-22M high speed freezing centrifuges, Shanghai Lu Xiang instrument centrifuge instruments
Co., Ltd.
2. experimental method：
(1) Animal Aging model modeling
By the raising of ICR mouse adaptability after a week, it is divided into 4 groups, every group 6.Group 1 is low dosage gavage group, and mouse is daily
D-gal is subcutaneously injected with the dosage nape part of 500mg/kg, and with the dosage gavage biologically active polypeptide in 1mg/ day
QPVLGPVRGP；Group 2 is high dose gavage group, and D-gal is subcutaneously injected with the dosage nape part of 500mg/kg daily in mouse, and
The day dosage gavage biologically active polypeptide QPVLGPVRGP of 3mg/ only；Group 3 is blank group, mouse normal growth；Group 4 is animal
D-gal is subcutaneously injected with the dosage nape part of 500mg/kg daily in model group, mouse, and the physiology that gavage concentration is 0.9%
Brine；The injection cycle of D-gal and the gavage cycle of polypeptide are 42 days.Bedding and padding are replaced, and ensure feed and distilled water within every 3 days
Supply.The every five days weight for weighing a mouse, D-gal parenteral solutions are prepared according to the weight of mouse, and D-gal parenteral solutions pass through
0.22 μm of needle cylinder type filter membrane filtering, it is sterile to ensure.
(2) animal viscera is obtained
After the completion of experimental period, to pluck the blood that eyeball blood taking method obtains mouse, disconnected neck puts to death mouse after obtaining blood, and
The body of mouse is placed on low temperature ice box afterwards, and wins brain, spleen, liver and the kidney of mouse rapidly, what is obtained is dirty
Device is placed in the 1.5mL centrifuge tubes that sterilize in advance, and all organ samples are maintained in -80 DEG C of refrigerators standby inspection.Disposal is real
All operations tested during animal follow Ministry of Science and Technology's issue in 2006《Directiveness meaning on kind treatment experimental animal
See》.The mouse spleen won directly is soaked in advance prepared 4% paraformaldehyde solution, in the form of fixing it.Poly
Formaldehyde powder more indissoluble, can add micro sodium acid carbonate and adjust pH value to alkalescence, with hydrotropy.Paraformaldehyde solution
Preparing needs to complete in fume hood.
(3) sample detection
The making of histotomy：Mouse spleen sample need at least be fixed in 4% paraformaldehyde solution 24 it is small when.Spleen group
The wax stone knitted makes, section entrusts Shanghai Wei Ao bio tech ltd to complete with HE dyeing.
3. experimental result and analysis：
In this experiment, 4 groups of mouse are shared, the mouse normal growth of wherein blank group is not affected by any environmental stimuli, its
3 groups of mouse of remaininging receive the long term injections of D-gal.Using light microscope, the spleen section of separate groups of mice is seen
Examine, can be found from Fig. 3, contrast the spleen section of each group mouse, for naive mice, the spleen of animal model mouse
Dirty red pulp is obscured with white pulp boundary, and atrophy occurs in white pulp, shows that the glycometabolism approach of mouse occurs for long-term D-gal injections
Disorder, causes anti-oxidant enzyme activity to reduce, peroxide accumulation, and then may trigger the aging and atrophy of spleen.And gavage is more
Then white pulp atrophy degree is lighter relative to animal model group mouse for the spleen tissue of the mouse of peptide group, and the boundary of red pulp and white pulp
It is more clearly demarcated.This result illustrates, in the injection cycle of whole D-gal, experiment animal sustained is constantly subject to cause senescence-factor
Stimulation, cause the aging and atrophy of spleen.Therefore from the point of view of the situation of changes in microstructure, the biology invented in this experiment
Active peptides QPVLGPVRGP has necessarily spleen aging of the animal caused by being subject to the stimulation of the bad factor with atrophy
Protective effect.
2nd, the experiment that biologically active polypeptide QPVLGPVRGP acts on intracorporeal organ antioxidant levels
1. experiment reagent and instrument：
Reagent：Experimental animal ICR mouse (male 5 week old), Shanghai City Experimental Animal Center；D-gal, Chinese medicines group chemistry
Reagent Co., Ltd；Paraformaldehyde, Sinopharm Chemical Reagent Co., Ltd.；Sodium chloride, the limited public affairs of Chinese medicines group chemical reagent
Department；The milk-derived biologically active polypeptide QPVLGPVRGP that embodiment 1 obtains；BCA protein reagent boxes, Nanjing Keygen Biotech's science and technology have
Limit company；MDA lipid peroxide kits, Science and Technology Ltd. of Nanjing Keygen Biotech；SOD superoxide dismutase reagents
Bio tech ltd is built up in box, Nanjing；T-AOC antioxidative activities kits, bio tech ltd is built up in Nanjing.
Instrument and equipment：The ultra-clean water of CM-230 types mole, Shanghai Moller scientific instrument Co., Ltd；Mi Libo Millipore
MILLEX GP0.22 μm filter membranes, Millipore Corp. of the U.S.；GL-22M high speed freezing centrifuges, Shanghai Lu Xiang instrument centrifuge instruments
Co., Ltd.
2. experimental method：
(1) Animal Aging model modeling
By the raising of ICR mouse adaptability after a week, it is divided into 4 groups, every group 6.Group 1 is low dosage gavage group, and mouse is daily
D-gal is subcutaneously injected with the dosage nape part of 500mg/kg, and with the dosage gavage biologically active polypeptide in 1mg/ day
QPVLGPVRGP；Group 2 is high dose gavage group, and D-gal is subcutaneously injected with the dosage nape part of 500mg/kg daily in mouse, and
The day dosage gavage biologically active polypeptide QPVLGPVRGP of 3mg/ only；Group 3 is blank group, mouse normal growth；Group 4 is animal
D-gal is subcutaneously injected with the dosage nape part of 500mg/kg daily in model group, mouse, and the physiology that gavage concentration is 0.9%
Brine；The injection cycle of D-gal and the gavage cycle of polypeptide are 42 days.Bedding and padding are replaced, and ensure feed and distilled water within every 3 days
Supply.The every five days weight for weighing a mouse, D-gal parenteral solutions are prepared according to the weight of mouse, and D-gal parenteral solutions pass through
0.22 μm of needle cylinder type filter membrane filtering, it is sterile to ensure.
(2) animal viscera is obtained
After the completion of experimental period, to pluck the blood that eyeball blood taking method obtains mouse, disconnected neck puts to death mouse after obtaining blood, and
The body of mouse is placed on low temperature ice box afterwards, and wins brain, spleen, liver and the kidney of mouse rapidly, what is obtained is dirty
Device is placed in the 1.5mL centrifuge tubes that sterilize in advance, and all organ samples are maintained in -80 DEG C of refrigerators standby inspection.Disposal is real
All operations tested during animal follow Ministry of Science and Technology's issue in 2006《Directiveness meaning on kind treatment experimental animal
See》.The mouse spleen won directly is soaked in advance prepared 4% paraformaldehyde solution, in the form of fixing it.Poly
Formaldehyde powder more indissoluble, can add micro sodium acid carbonate and adjust pH value to alkalescence, with hydrotropy.Paraformaldehyde solution
Preparing needs to complete in fume hood.
(3) sample detection
All internal organs that need to be detected, grind at low ambient temperatures, and 10% group is diluted to 4 DEG C of sterile PBS solutions
Knit homogenate, under the conditions of 4 DEG C after 4000g centrifugations, take supernatant, discard precipitation, operated according to kit specification, or put
It is to be measured in -80 DEG C of refrigerators.
3. experimental result and analysis：
The change of SOD contents in 3 each group experimental animal mouse Different Organs of table
Note：* sign is compared with model group, there is significant difference (P<0.05)；* signs are compared with model group,
There is significant difference (P<0.01), similarly hereinafter.
As can be known from Table 3, relative to animal model group mouse, the SOD in the liver and kidney of polypeptide gavage group mouse contains
Increase (the P of conspicuousness is presented in amount<0.01).Mean although the mouse of polypeptide gavage group is subject to the D-gal of long-term, high-dose
Stimulation, even if D-gal excess injection also without completely destroy Mice Body in SOD enzyme systems, illustrate in injection cycle, test
Animal can cause the reduction of SOD contents in Different Organs in the case of being continuously subject to cause the stimulation of senescence-factor, but together
When take in a certain amount of polypeptide QPVLGPVRGP there is certain protective role to the oxidative damage in Mice Body.
The situation of change of MDA contents in 4 each group experimental animal mouse Different Organs of table
As can be known from Table 4, the liver MDA content of animal model group mouse is 26.86 ± 7.64nmol/L, with animal model
Group compares, and significant difference (P is presented in the MDA contents in two groups of mouse livers of polypeptide gavage<0.01).Since MDA can be used for
Estimate the accumulation situation of animal body lipid peroxide, therefore it follows that animal model group mouse is causing aging model to be formed
During, due to the long term injections of excessive D-gal, the glycometabolism approach of mouse is got muddled, produce a large amount of free radicals from
And oxidative damage is caused, occur a large amount of lipid peroxide in its liver organization, MDA is as lipid peroxide, it is in animal
The rise of in-vivo content, can reflect the reduction of Antioxidant Enzymes vigor in Mice Body from side.And polypeptide gavage group Mouse Liver
Dirty MDA contents significantly reduce, and illustrate the intake of polypeptide QPVLGPVRGP and can effectively protect vital tissue organ from bad
The factor, which stimulates, produces substantial amounts of lipid peroxide.
The situation of change of T-AOC in 5 each group experimental animal Mice Body of table
As known from Table 5, the liver T-AOC values of animal model group mouse are 0.68 ± 0.23U/mgprot, are compared to mould
Significant difference (P is presented with low dosage gavage group mouse in type group, polypeptide high dose therewith<0.05)；The kidney of naive mice
Dirty T-AOC contents are 0.61 ± 0.24U/mgprot, and compared with animal model group mouse, low dosage gavage group presents aobvious therewith
Write sex differernce (P<0.05), significant difference (P is also presented in high dose gavage group mouse therewith<0.01).This result shows that, whole
In a experimental period, since experiment animal sustained is constantly stimulated be subject to cause senescence-factor, the liver of animal model group mouse,
Renal tissue is destroyed, and causes the reduction of its total antioxidant capacity.Compared with animal model group and blank group, polypeptide gavage group is small
The total antioxidant capacity of mouse major organs maintains a higher level all the time in the stimulating course for being subject to cause senescence-factor,
Illustrate that taking in biologically active polypeptide QPVLGPVRGP makes animal body and its major organs have higher self-protection function.
3rd, the experiment acted on immune cell factor in serum of biologically active polypeptide QPVLGPVRGP
1. experiment reagent and instrument：
Reagent：Experimental animal ICR mouse (male 5 week old), Shanghai City Experimental Animal Center；D-gal, Chinese medicines group chemistry
Reagent Co., Ltd；Paraformaldehyde, Sinopharm Chemical Reagent Co., Ltd.；Sodium chloride, the limited public affairs of Chinese medicines group chemical reagent
Department；The milk-derived biologically active polypeptide QPVLGPVRGP that embodiment 1 obtains；BCA protein reagent boxes, Nanjing Keygen Biotech's science and technology have
Limit company；ELISA cell factors Quick kit (TNF-α and IL-6), Wuhan Boster Biological Technology Co., Ltd..
Instrument and equipment：The ultra-clean water of CM-230 types mole, Shanghai Moller scientific instrument Co., Ltd；Mi Libo Millipore
MILLEX GP0.22 μm filter membranes, Millipore Corp. of the U.S.；GL-22M high speed freezing centrifuges, Shanghai Lu Xiang instrument centrifuge instruments
Co., Ltd.
2. experimental method：
(1) Animal Aging model modeling
By the raising of ICR mouse adaptability after a week, it is divided into 4 groups, every group 6.Group 1 is low dosage gavage group, and mouse is daily
D-gal is subcutaneously injected with the dosage nape part of 500mg/kg, and with the dosage gavage biologically active polypeptide in 1mg/ day
QPVLGPVRGP；Group 2 is high dose gavage group, and D-gal is subcutaneously injected with the dosage nape part of 500mg/kg daily in mouse, and
The day dosage gavage biologically active polypeptide QPVLGPVRGP of 3mg/ only；Group 3 is blank group, mouse normal growth；Group 4 is animal
D-gal is subcutaneously injected with the dosage nape part of 500mg/kg daily in model group, mouse, and the physiology that gavage concentration is 0.9%
Brine；The injection cycle of D-gal and the gavage cycle of polypeptide are 42 days.Bedding and padding are replaced, and ensure feed and distilled water within every 3 days
Supply.The every five days weight for weighing a mouse, D-gal parenteral solutions are prepared according to the weight of mouse, and D-gal parenteral solutions pass through
0.22 μm of needle cylinder type filter membrane filtering, it is sterile to ensure.
(2) animal viscera and serum are obtained
After the completion of experimental period, to pluck the blood that eyeball blood taking method obtains mouse, disconnected neck puts to death mouse after obtaining blood, and
The body of mouse is placed on low temperature ice box afterwards, mouse blood be stored at room temperature 1 it is small when after, with 3000g centrifuge 15min, separate blood
Clearly.Serum keeping is to be checked in -80 DEG C of refrigerators.All operations during disposal experimental animal follow the Ministry of Science and Technology in 2006
Issue《On treating the guiding opinion of experimental animal kindly》.The mouse spleen won directly is soaked in prepared in advance
In 4% paraformaldehyde solution, in the form of fixing it.Paraformaldehyde powder more indissoluble, can add micro sodium acid carbonate will
PH value is adjusted to alkalescence, with hydrotropy.The preparation of paraformaldehyde solution needs to complete in fume hood.
(3) sample detection
Indicated according to kit specification, draw standard curve first, standard items powder is prepared with standard dilutions
Into the solution of 1000pg/mL, then serial dilution is 500pg/mL, 250pg/mL, 125pg/mL, 62.5pg/mL, 31.3pg/mL,
15.6pg/mL wait various concentrations.Each concentration gradient solution pipettes 100 μ L in the ELISA Plate of coated antibody.Draw mouse
100 μ L of blood serum sample, add in same ELISA Plate (need to press when detecting calculating again if blood serum sample is inadequate, after can suitably diluting
Ratio is converted).ELISA Plate is covered, is placed under 37 DEG C of environment and is incubated 90min.After completion of the reaction, carefully get rid of in ELISA Plate
Liquid, and ELISA Plate is placed on blotting paper, it is careful to pat, remove surplus liquid.By preheated biotin antiantibody work
Make liquid to sequentially add in each hole of ELISA Plate by every 100 μ L of hole, at 37 DEG C, react 60min.After completion of the reaction, utilize 0.01M's
PBS solution is washed 3 times, adds the PBS of 100 μ L in every hole every time, and solution is removed in immersion 1min hypsokinesis, 3 times repeatedly.Will be preheated
ABC working solutions are sequentially added by every hole 0.1ml, 37 DEG C of reaction 30min.After completion of the reaction, 5 times are washed with 0.01M PBS, every time
Soak 1min or so.The TMB nitrite ions for balancing 30min at 37 DEG C are sequentially added by every 90 μ L of hole, 37 DEG C of lucifuges react 8-
12min.TMB terminate liquids are sequentially added by every hole 0.1ml, blueness is vertical at this time turns yellow, and OD values are measured in 450nm with microplate reader.
Concentration known is done by the standard protein of cell factor to be serially diluted, and standard curve is drawn out after measuring OD values, it is bent according to standard
Line can extrapolate the content of cell factor in sample.
3. experimental result and analysis：
The situation of change of cell factor in 6 each group mice serum of table
IL-6 and TNF-α content are respectively in the model group Mice Body being can be found that from table 6, Fig. 4, Fig. 5 in this experiment
168.01 ± 26.48pg/mL, 4.34 ± 0.36pg/mL, compared to the increase (P that conspicuousness is presented in normal group<0.01), therefore
It is considered that due to continuously injecting cause senescence-factor, animal model group mouse is caused aging occur in cell factor aspect
The symptom of property inflammation, and the IL-6 of the mice serum of polypeptide gavage group is effectively controlled with TNF-α content.According to cell because
The experimental result of son, serum levels of inflammatory cytokines IL-6, the secretion level of TNF-α of polypeptide gavage group mouse are below animal mould
Type group, from the point of view of oxidative damage angle, mouse because free radical attack, Peroxidation Product accumulation and caused by oxidative damage may obtain
Suppression to a certain extent；From the perspective of inflammation, mouse inflammation because of caused by oxidation has obtained effective suppression；From declining
From the point of view of old angle, a series of geriatric diseases caused by mouse aging caused by long term injections D-gal are possible to obtain
Control.
The above-mentioned description to embodiment is understood that for ease of those skilled in the art and using invention.
Person skilled in the art obviously easily can make these embodiments various modifications, and described herein general
Principle is applied in other embodiment without by performing creative labour.Therefore, the invention is not restricted to above-described embodiment, ability
Field technique personnel disclose according to the present invention, do not depart from improvement that scope made and modification all should be the present invention's
Within protection domain.
Sequence table
<110>Zhejiang Hui Tai life and healths Science and Technology Ltd.；Shanghai Bo Hui bio tech ltd
<120>A kind of biologically active polypeptide QPVLGPVRGP and its preparation method and application
<160> 3
<170> SIPOSequenceListing 1.0
<210> 1
<211> 10
<212> PRT
<213>Artificial sequence (Artificial Sequence)
<400> 1
Gln Pro Val Leu Gly Pro Val Arg Gly Pro
1 5 10
<210> 2
<211> 30
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 2
cagcctgtac tcggtcctgt ccggggacct 30
<210> 3
<211> 209
<212> PRT
<213>Artificial sequence (Artificial Sequence)
<400> 3
Arg Glu Leu Glu Glu Leu Asn Val Pro Gly Glu Ile Val Glu Ser Leu
1 5 10 15
Ser Ser Ser Glu Glu Ser Ile Thr Arg Ile Asn Lys Lys Ile Glu Lys
20 25 30
Phe Gln Ser Glu Glu Gln Gln Gln Thr Glu Asp Glu Leu Gln Asp Lys
35 40 45
Ile His Pro Phe Ala Gln Thr Gln Ser Leu Val Tyr Pro Phe Pro Gly
50 55 60
Pro Ile His Asn Ser Leu Pro Gln Asn Ile Pro Pro Leu Thr Gln Thr
65 70 75 80
Pro Val Val Val Pro Pro Phe Leu Gln Pro Glu Val Met Gly Val Ser
85 90 95
Lys Val Lys Glu Ala Met Ala Pro Lys His Lys Glu Met Pro Phe Pro
100 105 110
Lys Tyr Pro Val Gln Pro Phe Thr Glu Ser Gln Ser Leu Thr Leu Thr
115 120 125
Asp Val Glu Asn Leu His Leu Pro Pro Leu Leu Leu Gln Ser Trp Met
130 135 140
His Gln Pro His Gln Pro Leu Pro Pro Thr Val Met Phe Pro Pro Gln
145 150 155 160
Ser Val Leu Ser Leu Ser Gln Ser Lys Val Leu Pro Val Pro Glu Lys
165 170 175
Ala Val Pro Tyr Pro Gln Arg Asp Met Pro Ile Gln Ala Phe Leu Leu
180 185 190
Tyr Gln Gln Pro Val Leu Gly Pro Val Arg Gly Pro Phe Pro Ile Ile
195 200 205
Val
Claims (10)
1. a kind of biologically active polypeptide QPVLGPVRGP, it is characterised in that its amino acid sequence is Gln-Pro-Val-Leu-
Gly-Pro-Val-Arg-Gly-Pro。
2. a kind of biologically active polypeptide QPVLGPVRGP according to claim 1, it is characterised in that the bioactivity is more
Peptide is milk-derived.
3. encode the nucleotide fragments of biologically active polypeptide QPVLGPVRGP described in claim 1, it is characterised in that the nucleosides
The sequence of acid fragment such as SEQ ID NO：Shown in 2.
4. the preparation method of biologically active polypeptide QPVLGPVRGP as claimed in claim 1, it is characterised in that pass through genetic engineering
Method it is artificial synthesized, or directly obtained from dairy products by the method isolated and purified, or directly prepared by chemical synthesis.
5. the application of biologically active polypeptide QPVLGPVRGP as claimed in claim 1, it is characterised in that the biologically active polypeptide
Applications of the QPVLGPVRGP in the food with immunoloregulation function, health products, medicine or cosmetics are prepared.
6. the application of biologically active polypeptide QPVLGPVRGP as claimed in claim 1, it is characterised in that the biologically active polypeptide
Applications of the QPVLGPVRGP in the food with anti-senescence function, health products or medicine is prepared.
7. the application of biologically active polypeptide QPVLGPVRGP as claimed in claim 1, it is characterised in that the biologically active polypeptide
Applications of the QPVLGPVRGP in the food with immunoloregulation function and anti-senescence function, health products or medicine is prepared.
A kind of 8. immunological regulation product, it is characterised in that including biologically active polypeptide QPVLGPVRGP as claimed in claim 1 or
The derivative of the biologically active polypeptide QPVLGPVRGP；The immunological regulation product includes immunological regulation food, immune tune
Save health products, immunoregulation medicament or immunological regulation cosmetics；The derivative of the biologically active polypeptide QPVLGPVRGP, refers to
On the amino acid side groups of biologically active polypeptide QPVLGPVRGP, aminoterminal or c-terminus progress hydroxylating, carboxylated, carbonyl
Base, methylate, acetylation, phosphorylation, esterification or glycosylation modified, obtained polypeptide derivative.
9. a kind of anti-aging product, it is characterised in that including biologically active polypeptide QPVLGPVRGP as claimed in claim 1 or institute
State the derivative of biologically active polypeptide QPVLGPVRGP；The anti-aging product includes antisenility cistanche food, antisenescence health product
Or antiaging agent；The derivative of the biologically active polypeptide QPVLGPVRGP, refers in biologically active polypeptide QPVLGPVRGP
Amino acid side groups on, aminoterminal or c-terminus carry out hydroxylating, carboxylated, be carbonylated, methylate, acetylation, phosphoric acid
Change, esterification or glycosylation modified, obtained polypeptide derivative.
10. a kind of product with immunoloregulation function and anti-senescence function, it is characterised in that including as claimed in claim 1
The derivative of biologically active polypeptide QPVLGPVRGP or described biologically active polypeptides QPVLGPVRGP；With immunoloregulation function and
The product of anti-senescence function includes food, health products or medicine；The derivative of the biologically active polypeptide QPVLGPVRGP, refers to
On the amino acid side groups of biologically active polypeptide QPVLGPVRGP, aminoterminal or c-terminus progress hydroxylating, carboxylated, carbonyl
Base, methylate, acetylation, phosphorylation, esterification or glycosylation modified, obtained polypeptide derivative.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711319270.9A CN108017707B (en) | 2017-12-12 | 2017-12-12 | Bioactive polypeptide QPVLGPVRGP, and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711319270.9A CN108017707B (en) | 2017-12-12 | 2017-12-12 | Bioactive polypeptide QPVLGPVRGP, and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108017707A true CN108017707A (en) | 2018-05-11 |
| CN108017707B CN108017707B (en) | 2020-04-14 |
Family
ID=62072978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711319270.9A Active CN108017707B (en) | 2017-12-12 | 2017-12-12 | Bioactive polypeptide QPVLGPVRGP, and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108017707B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112759635A (en) * | 2021-01-21 | 2021-05-07 | 浙江辉肽生命健康科技有限公司 | Bioactive peptide with amino acid structure VAKVTGGAASKL, and preparation method and application thereof |
| CN112812171A (en) * | 2021-01-22 | 2021-05-18 | 浙江辉肽生命健康科技有限公司 | Bioactive peptide with amino acid structure VVRKPLNKEGKKP, and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1566152A (en) * | 2003-06-10 | 2005-01-19 | 天津商学院 | Immunoreactive peptide Trpi possessing antibacterial action |
| RU2415943C1 (en) * | 2010-02-16 | 2011-04-10 | Оксана Васильевна Козлова | Biologically active peptide prepared of lactic protein |
-
2017
- 2017-12-12 CN CN201711319270.9A patent/CN108017707B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1566152A (en) * | 2003-06-10 | 2005-01-19 | 天津商学院 | Immunoreactive peptide Trpi possessing antibacterial action |
| RU2415943C1 (en) * | 2010-02-16 | 2011-04-10 | Оксана Васильевна Козлова | Biologically active peptide prepared of lactic protein |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112759635A (en) * | 2021-01-21 | 2021-05-07 | 浙江辉肽生命健康科技有限公司 | Bioactive peptide with amino acid structure VAKVTGGAASKL, and preparation method and application thereof |
| CN112812171A (en) * | 2021-01-22 | 2021-05-18 | 浙江辉肽生命健康科技有限公司 | Bioactive peptide with amino acid structure VVRKPLNKEGKKP, and preparation method and application thereof |
| CN112812171B (en) * | 2021-01-22 | 2022-04-08 | 浙江辉肽生命健康科技有限公司 | Bioactive peptide with amino acid structure VVRKPLNKEGKKP, and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108017707B (en) | 2020-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108017702A (en) | A kind of biologically active polypeptide FPPQSVLS and its preparation method and application | |
| CN109160944A (en) | A kind of biologically active polypeptide ATAVPIIFF and its preparation method and application | |
| CN109053868A (en) | A kind of biologically active polypeptide DIENIKITGEI and its preparation method and application | |
| CN108794598A (en) | A kind of biologically active polypeptide NARIQDNLYLAV and its preparation method and application | |
| CN107176995A (en) | A kind of biologically active polypeptide SKVLPVPEKAVPYPQ and its preparation method and application | |
| CN107200780A (en) | A kind of biologically active polypeptide LVYPFPG and its preparation method and application | |
| CN107226860A (en) | A kind of biologically active polypeptide SKHSSLDCVL and its preparation method and application | |
| CN107236031A (en) | A kind of biologically active polypeptide PMIGVNQELAY and its preparation method and application | |
| CN107163136A (en) | A kind of biologically active polypeptide WNIPMGLIVNQ and its preparation method and application | |
| CN107226857A (en) | A kind of biologically active polypeptide TIASGEPT and its preparation method and application | |
| CN107746428A (en) | A kind of biologically active polypeptide DERFFSDKIA and its preparation method and application | |
| CN108017701A (en) | A kind of biologically active polypeptide FPKYPVEPF and its preparation method and application | |
| CN107759681A (en) | A kind of biologically active polypeptide INNQFLPYPYYAKPA and its preparation method and application | |
| CN107141346A (en) | A kind of biologically active polypeptide ATLEDSPEVI and its preparation method and application | |
| CN107200782A (en) | A kind of biologically active polypeptide VAVVKKGSNFQ and its preparation method and application | |
| CN108794590A (en) | A kind of biologically active polypeptide EPGIVNLD and its preparation method and application | |
| CN108997483A (en) | A kind of biologically active polypeptide DQDLVLI and its preparation method and application | |
| CN107188949A (en) | A kind of biologically active polypeptide EINTVQVTST and its preparation method and application | |
| CN107814839A (en) | A kind of biologically active polypeptide PIGSENSEKTTMPL and its preparation method and application | |
| CN108794602A (en) | A kind of biologically active polypeptide PNIMVIQH and its preparation method and application | |
| CN107840880A (en) | A kind of biologically active polypeptide GLNYYQQKPVA and its preparation method and application | |
| CN108017707A (en) | A kind of biologically active polypeptide QPVLGPVRGP and its preparation method and application | |
| CN108341855A (en) | A kind of biologically active polypeptide ADVKIGNDTVIEGN and its preparation method and application | |
| CN107903316A (en) | A kind of biologically active polypeptide LPYPYYA and its preparation method and application | |
| CN107827972A (en) | A kind of biologically active polypeptide SPEVIESPPEIN and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |